Why the first year gives a misleading picture

If both treatments feel equally effective for the first year, the choice between them can seem academic. Many patients who had microfracture in the early 2010s will report that it worked — and in the short term, they are right. Published data confirm that ChondroFiller injection and microfracture produce broadly comparable pain relief and functional gains through the first twelve months. That symmetry is genuine, not a statistical artefact, and it explains why older studies, which often stopped measuring at one year, appeared to validate microfracture as a reliable long-term answer.

The problem surfaces later. Functional scores after microfracture begin separating from those after ChondroFiller injection at around the two-year mark, then continue to diverge through years three to five. The short-term data window — the one most patients remember and many older trials captured — simply does not reach the point where the two trajectories part ways.

For anyone weighing these options now, the clinically meaningful comparison starts at year two, not year one.

The biology behind microfracture's ceiling

Microfracture does something deliberate and, in the short term, useful: it punctures the subchondral bone plate with a surgical pick so that blood and marrow leak into the cartilage defect, forming a clot. That clot carries mesenchymal stem cells, and it is these cells — not true chondrocytes — that populate the repair site. The distinction matters enormously. Mesenchymal stem cells that migrate into a cartilage defect differentiate into fibrochondrocytes, a cell type that produces fibrocartilage rather than native hyaline cartilage. The resulting tissue is dominated by Type I collagen — the same structural protein found in scar tissue and tendons — and is markedly deficient in glycosaminoglycans.

Glycosaminoglycans are the molecules that give healthy cartilage its load-bearing character. They attract and retain water within the matrix, allowing the tissue to absorb compressive forces and spring back after loading. Fibrocartilage, lacking this water-binding architecture, cannot distribute joint load in the same way. Under the repetitive forces of walking and exercise, it progressively breaks down — not through any failure of surgical technique, but because the biology of the repair tissue is fundamentally mismatched to the demands placed on it.

The second problem is the bone itself. Breaching the subchondral plate does not leave the underlying bone unchanged: the disruption can alter bone density, remodelling patterns, and the structural integrity of the repair bed beneath the defect. These changes compound the deterioration of the overlying fibrocartilage and, critically, may compromise the bone environment that any future repair procedure would depend on.

Pooled clinical data record a 62% treatment failure rate at a median follow-up of four years. Microfracture retains a narrow evidence-supported role — young patients with small focal defects, typically under 2 cm² — but failure rates rise disproportionately as defect size increases, because the marrow clot cannot adequately stabilise a larger repair zone.

How the ChondroFiller injection works differently

The ChondroFiller injection takes a different route to the same repair site — one that does not require touching bone at all. Delivered as an outpatient procedure under ultrasound guidance, it involves injecting an acellular Type I/III collagen scaffold directly into the mapped cartilage defect. Within minutes, the liquid sets into a stable gel that conforms to the defect geometry and anchors in place.

From that point, the mechanism is biological rather than mechanical. The scaffold — a CE-marked Class III medical device used across the knee, hip, and a range of smaller joints — provides a structured three-dimensional matrix into which the patient's own progenitor cells migrate. Once embedded, those cells begin depositing new cartilage matrix over roughly six to twelve months, a process called matrix-induced chondrogenesis. No drilling, no deliberate bone trauma, no marrow clot. The scaffold recruits the repair response without triggering the subchondral disruption that drives microfracture's long-term problems.

The structural explanation for why the two outcome curves eventually part sits in that last point. Because the subchondral bone plate is left intact, the cascade of bony changes described in the previous section — altered remodelling patterns, intralesional osteophyte formation, a structurally compromised repair bed — does not occur. The platform that cartilage sits on remains stable, and the repair environment stays hospitable as the scaffold matures. Whether the tissue that forms is truly hyaline or more accurately described as hyaline-like is difficult to establish without long-term biopsy follow-up, which remains sparse; what is clear is that the intact bone architecture beneath it is not actively working against the repair.

Where the outcomes split: years two to five

Published data put numbers to the divergence that the biology predicts. Across four knee studies, mean IKDC scores improved by approximately 30 points following ChondroFiller injection — a figure that clears the 16.7-point threshold for a minimal clinically important difference, meaning the improvement is large enough to register as genuinely meaningful to patients rather than a statistical artefact. Structural imaging reflects the same picture: MRI MOCART scores, which assess how well a defect has been filled and how organised the repair tissue is, consistently favour ChondroFiller injection over isolated microfracture in mid-term follow-up. Across knee, hip, and small-joint indications, 70–85% of patients in published series report meaningful symptom relief at three years, with outcomes holding rather than declining.

Microfracture moves in the opposite direction across the same window. Cumulative joint loading accelerates the degradation of fibrocartilage as the repair tissue accumulates mechanical wear it is structurally unequipped to handle. The subchondral bone changes — osteophyte ingrowth into the defect, altered marrow signal on imaging — become clinically significant in this period and can narrow the options for any subsequent repair if the primary procedure fails. The pooled failure rate of 62% at a median of four years reflects this trajectory.

The evidence quality deserves an honest note. No large randomised controlled trial has directly compared ChondroFiller injection with microfracture beyond the short term; the microfracture failure data derive from pooled cohort analyses, and ChondroFiller's outcome figures come from published case series rather than head-to-head RCTs. The direction of the evidence is consistent, but its certainty is not absolute.

The five-year picture — and the honest limits of both

At the five-year mark, meta-analyses show that functional score differences between the two approaches cease to be statistically significant. Both procedures produce predominantly fibrocartilage at that horizon — not native hyaline cartilage — and the structural divergence described in the preceding years narrows enough to lose statistical significance in population data.

That convergence is worth stating plainly, because it defines where ChondroFiller injection's advantage actually sits: the two-to-five-year period, when better tissue organisation and an intact subchondral bone plate translate into less degradation and more stable symptom relief under sustained loading. For a 38-year-old runner or a 52-year-old who needs reliable knee function through a working decade, those three years are not incidental — they coincide with the most physically demanding window of most patients' lives.

The biopsy evidence carries its own caveat. Long-term histological data from ChondroFiller injection follow-up are sparse; the degree to which scaffold-induced repair approaches true hyaline cartilage, rather than hyaline-like tissue, remains a matter of degree rather than established fact.

What this means practically is that outcome predictions depend heavily on individual factors — defect size, joint alignment, age, and OA grade — and that no population-level comparison substitutes for a mapped assessment of the specific joint and lesion in question.

Getting the right assessment for your defect

Choosing between pathways hinges on variables that symptom scores alone cannot resolve. Defect size is the most immediate filter: microfracture has historically performed best below 2 cm², while ChondroFiller injection is indicated for suitable focal defects up to approximately 3 cm², with clinical evaluation report data extending that to 6 cm² in appropriate cases. Alignment, OA grade, and age all bear on the prognosis — a malaligned knee will continue to load a repair asymmetrically regardless of which scaffold fills the defect.

Prior procedures matter too, and prior microfracture particularly so. Subchondral bone damage from an earlier marrow-stimulation procedure can compromise the environment into which a subsequent repair must integrate, and this needs to be assessed directly rather than assumed from history alone.

MRI characterisation of the lesion — its depth, size, and the integrity of the underlying bone — is the starting point for any structured evaluation. Clinical assessment then layers on alignment, mechanical symptoms, and activity demands. That combination, rather than a single metric, determines which pathway is appropriate for a given joint.

For patients seeking that evaluation, specialist cartilage assessment and access to the ChondroFiller injection pathway are available at londoncartilage.com.